logo-loader

MaxCyte Inc

Receive alerts
Market:
AIM
Market Cap:
£61.69 m
Price
107.50 GBX
Change
0.00%
52 weeks high
200.00
52 weeks low
100.00

In brief

We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.

Deep dive We explore the investor case for growth companies

Snapshot

  • Developing experimental targeted treatment for cancer
  • First patient dosed in phase I trial in October 2017
  • Second MCY-M11 cohort began dosing in May 2019
  • Potential milestone payments in excess of US$450mln